Asthma and Chronic Obstructive Pulmonary Disease (COPD) are common diseases which seriously endanger people’s health and life. Inhalation and quick delivery to the lungs is the preferred mode of administration of drugs for the prevention and treatment of COPD and asthma.

In China, it is difficult to meet patients’ requirements due to drugs being imported. To improve the technology of inhalation in China, the 3rd inhalation China Symposium is now taking place on the 6th-7th May 2019. Industry professionals from China and overseas will gather to share their thoughts with other experts in the field to analyse and discuss the problems of inhalation technology and future of inhalation.

H&T Presspart will be attending the event and will also be giving a speech entitled “The future challenges facing respiratory drug delivery: “Stability and effective delivery of complex molecules and combinations meeting patient needs”. There will also be opportunities to display a range of respiratory delivery products and Presspart will be based at booth 3BB18.

As well as our full range of MDI components, Presspart will be showcasing PowdAir Plus, a patented capsule-based DPI, ideal for inhalation markets because of its advanced simplicity, ease of use and affordability. In developing markets, where demand for respiratory treatments is growing rapidly, there’s an increasing need to offer more choice to patients who use a dry powder inhaler (DPI).

If you would like to arrange a meeting with our team or to receive more information regarding Presspart’s speech, then please contact us.